News from the FDA/CDC

FDA: PrEP indication updated to include adolescents at risk of HIV infection

Publish date: May 17, 2018

 


2.2 HIV-1 screening for individuals receiving Truvada for HIV-1 PrEP

Screen all patients for HIV-1 infection before initiating Truvada for HIV-1 PrEP and at least once every 3 months while taking Truvada

2.5 Recommended dosage for HIV-1 PrEP

The dosage of Truvada in HIV-1 uninfected adults and adolescents weighing at least 35 kg is one tablet (containing 200 mg of FTC and 300 mg of TDF) once daily taken orally with or without food.

Pages

Recommended Reading

MicroRNAs flag liver damage in HIV-, HCV-infected persons
MDedge Internal Medicine
VIDEO: Women living with HIV have more myocardial steatosis, reduced diastolic function
MDedge Internal Medicine
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Internal Medicine
Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief
MDedge Internal Medicine
Comorbidity occurs earlier and more commonly with HIV infection
MDedge Internal Medicine
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Internal Medicine
Most HIV patients need treatment for acute HCV
MDedge Internal Medicine
New trial to assess HIV+/HIV+ kidney transplants
MDedge Internal Medicine
Emotional regulation training lowers risk of adolescents having sex
MDedge Internal Medicine
FDA approves epoetin alfa biosimilar to treat anemia
MDedge Internal Medicine